Plethora licenses urological treatment from Roche

Roche has granted Plethora, a UK-based speciality pharmaceutical company focused on the development of products for the treatment of urological disease, an exclusive license to PSD 506, an M2/3 muscarinic receptor subtype-selective antagonist for overactive bladder in women and benign prostatic hyperplasia (BPH) in men.

PSD 506 represents the first of a new generation of the antimuscarinic drug class that work by selective and potent antagonism of two receptors important for mediating over-excitability of human bladders: M2 and M3 muscarinic cholinoceptors. It has the potential to improve the inhibition of hyperactivity in urological tissues while sparing common antimuscarinic side-effects of dry mouth, GI disturbance and dizziness/confusion that are observed with current therapies in the class.

Single and multiple dose Phase I studies have been successfully completed, and over the next 18 months Plethora will be responsible for the Phase II clinical differentiation programmes.